Rejoni

aid: rejoni
name: Rejoni
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
image: https://cdn.prod.website-files.com/68a338214a8d0f9a68a471b5/68a360063a1179d6ecb188ec_Rejoni_tag_logo_White.svg
description: 'Rejoni, Inc. is a privately held, clinical-stage women''s health medical device company founded in June 2020
  by serial entrepreneur Amar Sawhney, PhD and Pramand LLC, and headquartered at 201 Burlington Road in Bedford, Massachusetts.
  It develops proprietary hydrogel-based biomaterial therapies for gynecological surgery, with a stated mission of protecting,
  preserving and healing the uterus. Its lead product, the Juveena Hydrogel System, is designed to prevent the formation and
  reformation of intrauterine adhesions (IUAs) — the scar tissue that forms after transcervical procedures such as dilation
  and curettage, myomectomy or treatment of heavy bleeding, and a leading cause of infertility and abnormal uterine bleeding.
  The system pairs a low-profile proprietary transcervical catheter with two liquid precursors that cross-link on delivery
  into a soft, temporary hydrogel implant that mechanically separates the uterine walls during healing and then resorbs on
  its own in roughly two to three weeks, about one menstrual cycle, so no removal procedure is required. Juveena is investigational
  only and pending FDA approval; the FDA filed Rejoni''s premarket approval (PMA) application in January 2026, and the company
  completed patient enrollment in its US IDE pivotal study. Rejoni closed a $25 million financing in June 2026 with ClavystBio,
  Amed Ventures, Ascension Ventures, Catalyst Health Ventures, Delos Capital, FemHealth Ventures, Iyengar Capital and Sparta
  Group, and appointed women''s health MedTech leader John Nealon as chief executive officer in May 2026. Rejoni runs no developer
  program and publishes no public API: its entire web presence is a small Webflow marketing site, and probes for OpenAPI,
  Swagger, GraphQL, MCP, llms.txt and every /.well-known/ discovery path returned HTTP 404 against a verified real-404 origin,
  while api./developer./docs./app./portal.rejoni.com resolve only to a wildcard A record with no listener answering on either
  port 80 or 443.'
url: https://raw.githubusercontent.com/api-evangelist/rejoni/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-05'
modified: '2026-08-05'
tags:
- Company
- Medical Devices
- Women's Health
- Healthcare
- Biomaterials
- Life Sciences
- Surgery
- Clinical Trials
- MedTech
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://rejoni.com/
- type: About
  url: https://rejoni.com/about
- type: Team
  url: https://rejoni.com/team
- type: Technology
  url: https://rejoni.com/technology
- type: News
  url: https://rejoni.com/news
- type: Contact
  url: https://rejoni.com/contact
- type: PrivacyPolicy
  url: https://rejoni.com/privacy
- type: LinkedIn
  url: https://www.linkedin.com/company/rejoni
- type: SecondaryMarket
  url: https://forgeglobal.com/rejoni_stock/
- type: DomainSecurity
  url: security/rejoni-domain-security.yml
- type: LLMsTxt
  url: llms/rejoni-llms.txt
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Rejoni's product is a resorbable hydrogel implant and a transcervical delivery catheter pending FDA premarket approval,
    not software; its whole web presence is a seven-page Webflow marketing site with an empty robots.txt, where /openapi.json,
    /graphql, /mcp, /llms.txt and every /.well-known/ path 404 against a verified real-404 control, and api./developer./docs.rejoni.com
    resolve only to a wildcard A record that never answers a TCP connect.
  evidence:
  - url: https://rejoni.com/openapi.json
    status: 404
  - url: https://rejoni.com/llms.txt
    status: 404
  - url: https://rejoni.com/.well-known/agent-card.json
    status: 404
  - url: https://rejoni.com/graphql
    status: 404
  - url: https://rejoni.com/zzz-control-path-check
    status: 404
  - url: https://api.rejoni.com/
    status: 0
  checked: '2026-08-05'
x-enrichment:
  date: '2026-08-05'
  status: minimal
  artifacts_added: 3
  pass: local-v1